Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
University of Chicago
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
West China Hospital
M.D. Anderson Cancer Center
University of Chicago
Case Comprehensive Cancer Center
Sanford Health
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
The University of Texas Health Science Center, Houston
University of Wisconsin, Madison
West China Hospital
American College of Radiology
Medical College of Wisconsin
Dana-Farber Cancer Institute
Providence Health & Services
Providence Health & Services
University of California, San Diego
University of Chicago
Columbia University
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
University Medical Center Groningen
Providence Health & Services
Medical University of South Carolina
University Medical Center Groningen
King's College London
The Affiliated Hospital of Qingdao University
Suzhou Genhouse Bio Co., Ltd.
University College, London
Yale University
Providence Health & Services
Vanderbilt-Ingram Cancer Center
The Netherlands Cancer Institute
Oslo University Hospital
University of Alabama at Birmingham
Centre Georges Francois Leclerc
Emory University
Mayo Clinic
University of Chicago
Southern Tohoku BNCT Research Center
Stanford University
H. Lee Moffitt Cancer Center and Research Institute
University Hospital, Ghent
University Hospital, Ghent